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OpinionReversible, Spatial and Temporal Control
over Protein Activity Using LightMark W.H. Hoorens1,2 and Wiktor Szymanski1,2,*Highlights
Using light in medicine is increasingly
popular, due to the fact that light is
orthogonal with biological systems
and can be regulated and dosed
easily.
In the past 5 years, many bioactive
molecules with photo-controlled activ-
ity have been developed, and the ﬁeld
of photopharmacology is rapidly
expanding.
The chemical toolbox of photo-
switches is growing, with a special
interest in red-light-operated photo-
switches, since red and near-IR light
shows the highest tissue penetration.
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w.szymanski@umcg.nl (W. Szymanski).In biomedical sciences, the function of a protein of interest is investigated by
altering its net activity and assessing the consequences for the cell or organ-
ism. To change the activity of a protein, a wide variety of chemical and genetic
tools have been developed. The drawback of most of these tools is that they do
not allow for reversible, spatial and temporal control. Here, we describe
selected developments in photopharmacology that aim at establishing such
control over protein activity through bioactive molecules with photo-controlled
potency. We also discuss why such control is desired and what challenges still
need to be overcome for photopharmacology to reach its maturity as a chemi-
cal biology research tool.
The Limitations of the Traditional Tools to Study Protein Function
Cells, tissues, and organisms are highly complex systems in which several thousands of
proteins interact and play a role in a wide variety of processes such as metabolism, signaling,
homeostasis, and cell division. To understand the function of a protein of interest in both health
and disease, researchers alter its net activity and subsequently observe the resulting changes in
the biological system [1–3]. To change the protein activity, a wide variety of chemical and
genetic tools have been developed.
Bioactive molecules are widely used as chemical tools to modify the activity of native proteins.
The main advantage is that their solutions can conveniently be added to a cell culture or injected
into a model organism. For many proteins, bioactive molecules have been developed that can
activate or inhibit the activity via either competitive or allosteric mechanisms. Currently, the
Binding database (www.bindingdb.org) reports over 600 000 small molecules targeting over
7000 protein targets. However, drawbacks of using bioactive molecules include the lack of
reversibility and limited spatial control: the solutions are added systemically, and there is no
easy way to remove the bioactive molecule in a controlled manner, once it has been added.
Genetic tools for protein activity modulation, besides controlling the activity of native proteins,
can also change the concentration of the protein of interest at either the transcription level or the
translation level by (single or double) knockout, knockdown, and the use of siRNA [4]. However,
it is known for many proteins that knockouts in mice are lethal [5], which only demonstrates that
these proteins are crucial, without elucidating their role. Decreasing the activity can also be
achieved by making speciﬁc mutations in the active site, by a knockin, which results in a
catalytically inactive protein that still maintains its binding properties [6]. Increasing the con-
centration of proteins can be achieved through overexpression, resulting in higher net activity of
the protein of interest. Genetic tools, while widely applied, are elaborate in use. Yet, the rapidly
growing ﬁeld of clustered regularly interspaced short palindromic repeats/CRISPR-associated
protein 9 (CRISPR/Cas9) might allow easier modiﬁcation [7]. More advanced genetic techni-
ques are inducible expression systems in which addition of a chemical inducer such asTrends in Biochemical Sciences, August 2018, Vol. 43, No. 8 https://doi.org/10.1016/j.tibs.2018.05.004 567
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doxycycline changes the activity of a promotor and thereby the expression [8], which can be
returned to its original level by washing out of the chemical inducer. In conclusion, genetic tools
are mainly irreversible, that is, the concentration of knocked-out protein cannot be conveniently
restored to the natural level at a given time. Furthermore, the spatial resolution of protein
expression modiﬁcation is limited, meaning that, for example, a protein is knocked out
systemically and not in an organ- or tissue-speciﬁc manner.
Why Is Reversible, Spatial and Temporal Control over Protein Activity
Important?
Currently, the toolbox to alter protein activity relies mainly on irreversible techniques, as
discussed previously. Yet, reversibility can be of importance in elucidating the function of a
protein of interest. From an experimental point of view, reversibility serves as a strong control,
since the same system (cell, tissue, organism) can be studied over a short period of time with
and without the altered protein activity. Also, reversibility of modulation minimizes the irrevers-
ible downstream effects, which are observed for every alteration of a biological system and
depend on the duration of alteration. A well-established example is drug addiction in which long
dosage of an active compound results in a different response than the initial response [9,10].
Another typical example is how tumor cells can acquire drug resistance by activating alternative
pathways to bypass the inhibited pathway [11,12]. Compensation effects and their inﬂuence on
the observed biological outcome could be better understood when the duration of the inhibition
or activation is precisely controlled. Altogether, reversibility and temporal control over the
modulation will contribute to a better understanding of protein function in a biological system
with minimalized compensation effect.
Alteration of protein activity by genetic and chemical tools is mainly systemic. However, a
protein of interest might have a speciﬁc function in an organ or tissue. The systemic alteration of
the activity of a protein of interest provides observations that can be difﬁcult to trace back to a
speciﬁc local function. For example, for histone deacetylase 2 (HDAC2) it was shown that the
expression in the dorsolateral prefrontal cortex in schizophrenia patients is decreased [13].
Since HDAC2 is expressed in many tissues [14], systemic inhibition of HDAC2 in an animal
model does not help to elucidate the speciﬁc role of HDAC2 in this brain region. However, this
limitation could be overcome by locally inhibiting HDAC2 activity, mimicking the patient situation
more closely and contributing to a better understanding of the role of HDAC2 in speciﬁc brain
regions and their connection to other areas. Such site-speciﬁc alterations of the activity will also
have large implications in, for example, proving the site of action of drugs, studying cell
signaling, and understanding adverse effects of therapeutics.
Light Is an Emerging External Stimulus to Control Protein Activity
To achieve reversible, spatial and temporal control over protein activity, a modulator is needed
whose activity can be controlled with an external stimulus, such as photons. Light is already widely
used in biological studies, for example, in optical and ﬂuorescence microscopy, which is enabled
by the orthogonality of photons toward living systems and processes within them [15]. Even UV
light is, to a large extent, tolerated in cell cultures, as demonstrated by the imaging of the blue
ﬂuorescent protein [16] and DNA-labeling dye 40,6-diamidino-2-phenylindole (DAPI) [17]. Yet, it is
recommended to do control experiments in which the biological system is subjected to irradiation
only, to check for any undesired effects. The key beneﬁt of using light is that it is easily possible to
regulate when, where, for how long, and with which intensity and wavelength it is used.
Currently, there are several tools available to use light to gain control over the activity of proteins.
A well-established example is optogenetics, where responsive elements from photoactive568 Trends in Biochemical Sciences, August 2018, Vol. 43, No. 8
proteins are genetically engineered into other proteins, by which, for example, a receptor can
be activated with light instead of a chemical ligand [18]. The ﬁeld acknowledges the demand of
spatial and temporal control over the activity of biological pathways [19]. However, expressing
engineered proteins is challenging.
A chemical approach to acquire photocontrol is photocaging. A photocage is a photores-
ponsive chemical group that uses the energy of a photon to break a chemical bond [20]. A
photocage is placed at a functional group of a bioactive molecule [21] or amino acid of a protein
[22] by which it loses its activity; upon irradiation the photocage is removed, resulting in the
release of a biologically active molecule [23]. The approach of using photocaged bioactive
compounds was successfully demonstrated in vivo in a mouse model [24]. A drawback is that
the photochemical process of uncaging is irreversible.
A fully pharmacological, remote, and reversible control of protein activity with light is enabled
through the use of molecular photoswitches, that is, small photoresponsive molecules that upon
irradiation change their structure [25,26] (for a detailed explanation, see Box 1), hence the name
photoswitch. A widely used photoswitch is azobenzene in which the diazo bond (N¼N) is
connected to two phenyl rings that can be on its opposite sides (trans-azobenzene) or on the
same side (cis-azobenzene). The trans isomer is thermodynamically stable and be can switched
into the cis isomer by irradiation with UV light (Box 1). This process can be reversed spontaneously
using heat or the molecule can be switched back using visible light irradiation. The process of
switching from trans to cis and back can usually be repeated for many cycles [25,27].
The emerging ﬁeld of photopharmacology utilizes the differences in shape and chemical
properties between photo-isomers of a bioactive molecule that differ in activity (Figure 1,
Key Figure) and that can be interconverted with light irradiation and/or spontaneous thermal
relaxation [28]. Photoswitches such as azobenzene are introduced into the structure of the
bioactive molecule [29]. Through this, remote control over its activity, and therefore the activity
of the protein of interest, can be achieved. Photopharmacology mainly aims at developing
therapeutics that are only active at the target and not in healthy tissue, to eliminate activity of
drugs in healthy tissue and its consequences [30]. However, besides this potential clinical
application, bioactive molecules with photocontrolled activity can serve as a powerful tool in
biomedical research. These remotely controlled bioactive molecules can simply be pipetted to
a cell culture or injected into a model organism; afterwards, by precise irradiation, control over
protein activity is acquired. In the following, we look at examples from the protein classes of
enzymes, structural proteins, and receptors for which photopharmacological control has been
established either in vitro or in vivo.
Photo-control over Enzymatic Activity
Enzymes are the workhorses of the cell and harbor many regulatory functions and processes
that are often dysregulated in disease. To demonstrate photopharmacological control over
enzyme activity, the speciﬁc case of HDAC2 is discussed here. This enzyme is a member of the
histone deacetylase family, which is involved in epigenetic regulation of gene expression [31]. In
several cancers, increased expression of HDAC2 is observed, resulting in decreased expres-
sion of genes with antitumor activity [14]. Therefore, inhibition of HDAC2 has been shown to be
effective in killing tumor cells [32], like, for example, the FDA-approved HDAC2 inhibitor
vorinostat for the treatment of metastatic melanoma [33].
Traditional genetic and chemical toolboxes have been used to study the speciﬁc role of HDAC2.
Unfortunately, HDAC2 knockout mice die of cardiac malfunction the ﬁrst day after birth [32],Trends in Biochemical Sciences, August 2018, Vol. 43, No. 8 569
Box 1. Understanding Light-Controlled Drugs: Molecular Structure and Photochemistry
Azobenzene (A) is the most-often-used molecular photoswitch in photopharmacology and serves here as an example to
introduce the behavior of molecular photoswitches. Azobenzene has two isomers: the thermally stable trans isomer
(blue) and the thermally unstable cis isomer (orange). These two forms differ in structure, polarity, solubility, and many
other features.
Importantly, their UV-visible spectra are also different (B), which leads to the possibility of selectively addressing each of
the forms with light. The trans form shows a strong absorption band at low wavelengths (denoted as l1; typically, UV
light of 320–370 nm), where the absorption of the cis form is lower. At higher wavelengths (denoted as l2; typically,
visible light of 420–480 nm) the cis form absorbs more strongly than the trans form. Using l1, it is usually possible to
selectively switch the trans form to the cis form. With l2, the cis form can selectively be switched back to trans.
The ﬁrst of these processes is discussed in more detail in (C). When light of l1 is applied, the trans form absorbs the
photon and enters the excited state, from which it can relax to the ground state of the cis form. The kinetics of this
process depends on (i) the probability of absorbing the photon, represented by the extinction coefﬁcient ; and (ii) the
probability that, once in the excited state, it will fall to ground state with isomerization, represented by the trans-to-cis
isomerization quantum yield wt!c. While the concentration of the cis form increases, it also absorbs light, with extinction
coefﬁcient of , and with the quantum yield of wc!t, it can isomerize back to trans. In time, a dynamic equilibrium is
established between the two processes. Assuming negligible thermal cis–trans reisomerization on the timescale of the
experiment, the position of this equilibrium is described by the photo-stationary state (PSS), which is simply the
percentage of compounds that are in the cis state at equilibrium under irradiation.
Once the light is switched off (D), the molecular photoswitch returns to its original state, which is usually >99% of the
stable trans form. This recovery is a ﬁrst-order process, and the time needed to isomerize half of the cis compounds
back to trans is described as half-life (t0.5). This value depends both on the structure of the photoswitch and on its
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εdemonstrating the importance of the protein, but not its speciﬁc function. To decrease the
HDAC2 activity pharmacologically, a wide variety of inhibitors have been developed with
selectivity for HDAC2 over other HDACs from the same protein family [33]. Recently, a
photocaged variant of vorinostat was developed by which spatial and temporal control over
HDAC2 activity can be achieved [34], however irreversibly.570 Trends in Biochemical Sciences, August 2018, Vol. 43, No. 8
Key Figure














Figure 1. (A) A model of photopharmacology. An inhibitor containing a photoswitch in its ‘off’ state (blue) has no strong interactions with the target; however, in the ‘on’
state (orange), the inhibitor binds strongly. Light of wavelength l1 switches the inhibitor from the off state to the on state, and light of wavelength l2 reverses this process.
(B) Dose–response curve of a bioactive molecule with photo-controlled activity as shown in (A). The on state (orange) is potent at lower concentration than the off state
(blue), and it is possible to switch between those states using light and thermal relaxation processes. At a carefully chosen concentration, [I]opt, the on state nearly fully
inhibits the activity, while the protein of interest is at almost full activity for the off state.To achieve the desired reversible, spatial and temporal control over HDAC2 activity, our lab
developed HDAC2 inhibitors with photo-controlled activity [35], as shown in Figure 2. For
compound 1, the cis isomer is 39 times more active than the trans isomer. The difference in
cytotoxic activity between trans and cis was also observed in HeLa cells, even showing a larger
difference in cell viability than for the individual HDAC2 inhibitor. Also, reversibility and temporal
control over the activity of HDAC2 were demonstrated, overcoming the limitations of the current
chemical and genetic toolbox.
Can Bioactive Molecules with Photo-controlled Activity Be Developed for
Every Protein?
Currently, there are hundreds of thousands of small molecule compounds that can modulate
the activity of several thousands of target proteins. In contrast, only several dozens of
bioactive molecules with photo-controlled activity have been developed [30]. However,
the number is rapidly growing, and the list of protein targets is expanding. Photo-control
over the activity of members of protein families such as enzymes [36,37], receptors [38–42],
transporters [43], and structural proteins [44–47] has been achieved, demonstrating the
generality of this approach. The design is usually based on known protein modulators that do
not harbor photo-control. As shown by two examples in Figure 3, chemical structures similar
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Figure 3. Examples of Bioactive Molecules with Photo-controlled Activity. (A) Light control of a structural protein: formation of microtubule. Based on tubulin
polymerization inhibitor combretastatin A4, compounds 2a and 2b were designed. Upon irradiation with UV light, compound 2b becomes 550 times more active, which
can be reversed using visible light irradiation [46]. (B) Compound 2a induced the breakdown of tubulin (green) and fragmentation of the nucleus upon irradiation with
390 nm to the active cis isomer and 20-h incubation, while irradiation without inhibitor and the trans isomer of compound 2a do not change the physiology of the cell.
Adapted from [45]. (C) Light control of receptor activity: metabotropic glutamate receptor 5 (mGlu5). Based on negative allosteric modulator VU0414374, compound 3
was designed. Upon irradiation with UV light, compound 3 becomes 5.1 times less active, which can be reversed using visible light [40]. (D) Persistent inﬂammatory pain
was induced in a mouse model, and after 10 days the number of paw lifts was recorded (naive) and normalized to healthy mice (vehicle) with and without irradiation in the
amygdala. Injection of compound 3 resulted in the same behavior in the mouse as in naive mice; upon irradiation to the cis isomer, this effect could be abolished, to the
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Figure 2. Photo-control over the Activity of Histone Deacetylase 2 (HDAC2). (A) Based on known HDAC2 inhibitor vorinostat, compound 1 was designed.
Upon irradiation, compound 1 switches from trans to cis form, becoming 39-fold more active as an HDAC2 inhibitor. (B) Dose–response curve for compound 1 in trans
(blue) and cis (orange) form on cell viability of HeLa cells. Reproduced, with permission, from [35].
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approach called azologization [48]. This approach has been extended to other chemical
structures with less similarity to the structure of the photoswitch, guided by structure–activity
relationship studies and computational support [40,42,49]. So far, the development of
bioactive molecules with photo-controlled activity is limited by the availability of known
modulators and the existence in those modulators of structural features that can be replaced
by a photoswitch without a major loss in potency.
The replacement of a fragment of a molecule by a photoswitch has been convincingly
demonstrated by taking advantage of the structural similarity of natural compound combre-
tastatin A4 and cis-azobenzene [44,47] (Figure 3A). Combretastatin A4 is an inhibitor of
microtubule formation. Microtubules belong to the family of structural proteins and are an
important compartment of the cytoskeleton, playing a role in mechanical processes such as the
intracellular transport of vesicles and separation of chromosomes in mitosis [50]. Azologization
of combretastatin A4 resulted in an inhibitor with photo-controlled activity (Figure 3A), where
irradiation of the inactive trans isomer to the cis isomer increases the potency in HeLa cells in
vitro by an impressive factor of 550 for compound 2b [47].
Reversible spatial and temporal control over protein activity shows its full potential in an in vivo
model. Recently, several in vivo studies of photopharmacological agents have been reported,
mainly for neurological targets, such as restoring the visual function of the blind retina [51], and
metabotropic glutamate receptors [40,52]. An impressive example of an in vivo-tested bioac-
tive molecule with photo-controlled activity was reported by the groups of Gorostiza and
Llebaria, targeting metabotropic glutamate receptor 5 [40,49,53–55], which is a potential target
for the treatment of anxiety, depression, and schizophrenia [56,57]. Inspired by negative
allosteric modulator VU0414374, compound 3 was designed (Figure 3C) and tested in an
in vivo system using hybrid optic and ﬂuid cannulas that were implanted in the amygdala of
persistent inﬂammatory pain mouse model. The mouse was injected with compound 3 in the
amygdala in the active trans conﬁguration, resulting in an analgesic effect. This pain-relieving
effect could be abolished by irradiation to the inactive cis isomer [40]. By this, photo-control
over pain in a rodent model was achieved, which opens opportunities in studying pain, its
development, and its treatment.
The Current Limitation of Photoswitchable Bioactive Molecules as a
Research Tool
A challenge in the development of bioactive molecules with photo-controlled activity is to
acquire large differences in activity between the photo-isomers. As shown in Figure 1B, at a
precisely chosen concentration, [I]opt, one isomer does not change the activity of the protein of
interest, while the other isomer results in complete inhibition of protein activity; hence, the
protein can be switched fully on and fully off. However, this optimal situation of fully switching is
rarely achieved. For example, for compound 1, a 39-fold difference in activity between the trans
and cis isomer is not yet sufﬁcient to allow for switching between fully active HDAC2 and fully
inhibited HDAC2 [35]. In the optimization of photopharmacological agents, every chemical
modiﬁcation of the bioactive molecule potentially not only changes the biological activity but
also the chemical properties and important photochemical properties such as the absorption
maxima, half-life of the cis isomer, quantum yield, and the photo-stationary states (PSSs). This
optimization process is challenging; yet, to reach full potential as a research tool, differences in
the activity between isomers should be enhanced.
Another challenge is that most of the photopharmacological agents need UV light in the region of
350–400 nm to switch [30]. Such light has a limited penetration depth of only a few millimeters inTrends in Biochemical Sciences, August 2018, Vol. 43, No. 8 573
Outstanding Questions
Currently, most bioactive molecules
with photo-controlled activity have a
difference in activity between the
photo-isomers of about 10–50-fold.
So, how do we rationally design new
compounds with a larger difference in
activity?
Even though there is a difference in
activity between both photo-isomers,
usually both can bind to the target.
Does the bioactive molecule with
photo-controlled activity switch while
bound, or does it ﬁrst have to dissoci-
ate from the target protein?
How can effective and preferably non-
invasive irradiation of bioactive mole-
cules with photo-controlled activity be
achieved in deep organs of model
organisms?
How does diffusion of bioactive mole-
cules compromise the spatial resolu-
tion provided by light? And in which
range should the half-life of the bioac-
tive molecules be to prevent this?
Since the photochemical properties of
a compound strongly depend on its
environment, how can we determine
the ratio of photo-isomers in vivo?soft tissue [58]. This is sufﬁcient for experiments in monolayer cell culture, but not for animal
models, since most inner organs cannot be reached in a noninvasive manner. However, red and
near-IR light has deeper penetration depth in soft tissue, up to several centimeters [58]. Therefore,
red-light-responsive photoswitches and photopharmacological agents are in development [59–
61]. Recently, an elegant example was published by the Feringa group [62], where an antibiotic
was developed that increases eight times in potency upon irradiation with red light.
Concluding Remarks and Future Prospects
In addition to the three examples described here, for many other proteins, bioactive molecules
with photo-controlled activity have been developed in recent years. Besides their potential
clinical applications in photopharmacology, these are powerful tools for biomedical research,
because light is orthogonal with biological systems, no genetic modiﬁcations are required, and
spatial and temporal control can be achieved in a reversible manner. The broad range of
proteins that can be altered by photopharmacology and especially the reversibility of the
modiﬁcation can make it a superior tool compared to the existing toolbox.
More bioactive molecules with photo-controlled activity will be developed, with a focus on
visible light switching and optimization of the difference in activity between isomers. In parallel,
new photoswitches that can be operated with visible light or that have enlarged differences in
structure between isomers are being discovered. These developments will, more and more,
allow photo-controlled bioactive molecules in biomedical research to contribute to the under-
standing of the role of a protein of interest in health and disease.
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